Benoy Ina H, Salgado Roberto, Elst Hilde, Van Dam Peter, Weyler Joost, Van Marck Eric, Scharpé Simon, Vermeulen Peter B, Dirix Luc Y
Translational Cancer Research Group Antwerp, Laboratory of Pathology, University of Antwerp/University Hospital Antwerp, Edegem, Belgium.
Breast Cancer Res. 2005;7(2):R210-9. doi: 10.1186/bcr980. Epub 2005 Jan 10.
About 50% of patients with breast cancer have no involvement of axillary lymph nodes at diagnosis and can be considered cured after primary locoregional treatment. However, about 20-30% will experience distant relapse. The group of patients at risk is not well characterised: recurrence is probably due to the establishment of micrometastases before treatment. Given the early steps of metastasis in which tumour cells interact with endothelial cells of blood vessels, and, given the independent prognostic value in breast cancer of both the quantification of tumour vascularisation and the detection of micrometastases in the bone marrow, the aim of this study was to determine the relationship between vascularisation, measured by Chalkley morphometry, and the bone marrow content of cytokeratin-19 (CK-19) mRNA, quantified by real-time reverse transcriptase polymerase chain reaction, in a series of 68 patients with localised untreated breast cancer. The blood concentration of factors involved in angiogenesis (interleukin-6 and vascular endothelial growth factor) and of factors involved in coagulation (D-dimer, fibrinogen, platelets) was also measured. When bone marrow CK-19 relative gene expression (RGE) was categorised according to the cut-off value of 0.77 (95th centile of control patients), 53% of the patients had an elevated CK-19 RGE. Patients with bone marrow micrometastases, on the basis of an elevated CK-19 RGE, had a mean Chalkley count of 7.5 +/- 1.7 (median 7, standard error [SE] 0.30) compared with a mean Chalkley count of 6.5 +/- 1.7 in other patients (median 6, SE 0.3) (Mann-Whitney U-test; P = 0.04). Multiple regression analysis revealed that Chalkley count, not lymph node status, independently predicted CK-19 RGE status (P = 0.04; odds ratio 1.38; 95% confidence interval 1.009-1.882). Blood parameters reflecting angiogenesis and coagulation were positively correlated with Chalkley count and/or CK-19 RGE. Our data are in support of an association between elevated relative microvessel area of the primary tumour and the presence of bone marrow micrometastases in breast cancer patients with operable disease, and corroborate the paracrine and endocrine role of interleukin-6 and the involvement of coagulation in breast cancer growth and metastasis.
约50%的乳腺癌患者在诊断时腋窝淋巴结未受累,经局部区域初次治疗后可视为治愈。然而,约20% - 30%的患者会出现远处复发。有复发风险的患者群体特征尚不明确:复发可能是由于治疗前已形成微转移灶。鉴于肿瘤细胞与血管内皮细胞相互作用是转移的早期步骤,且鉴于肿瘤血管生成的量化以及骨髓中微转移灶的检测在乳腺癌中均具有独立的预后价值,本研究的目的是在68例未经治疗的局部乳腺癌患者中,确定通过Chalkley形态计量法测量的血管生成与通过实时逆转录聚合酶链反应定量的细胞角蛋白-19(CK-19)mRNA的骨髓含量之间的关系。还测量了参与血管生成的因子(白细胞介素-6和血管内皮生长因子)以及参与凝血的因子(D-二聚体、纤维蛋白原、血小板)的血浓度。当根据0.77的临界值(对照患者的第95百分位数)对骨髓CK-19相对基因表达(RGE)进行分类时,53%的患者CK-19 RGE升高。基于CK-19 RGE升高诊断为骨髓微转移的患者,其Chalkley计数的平均值为7.5±1.7(中位数7,标准误[SE] 0.30),而其他患者的Chalkley计数平均值为6.5±1.7(中位数6,SE 0.3)(Mann-Whitney U检验;P = 0.04)。多元回归分析显示,Chalkley计数而非淋巴结状态可独立预测CK-19 RGE状态(P = 0.04;优势比1.38;95%置信区间1.009 - 1.882)。反映血管生成和凝血的血液参数与Chalkley计数和/或CK-19 RGE呈正相关。我们的数据支持在可手术治疗的乳腺癌患者中,原发肿瘤相对微血管面积升高与骨髓微转移灶的存在之间存在关联,并证实了白细胞介素-6的旁分泌和内分泌作用以及凝血在乳腺癌生长和转移中的参与。